Program
Lisinopril
Also written as “LP-003 Injection”, “lisinopril” and “LP-005 Injection”.
Its studies are mostly in Hypertension · Chronic Urticaria · Hemoglobinuria, Paroxysmal · Fasting · Rhinitis, Allergic, Seasonal, led by 10 companies.
Drug pageLisinopril: every studyMany companies study it; this page follows only the 39 they lead. All 79 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Longbio Pharmaits history only | 149 open or running | phase 3since Dec 5, 2025 | Jun 27, 2023 | Nov 2026phase 1 · NCT06604949 |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Apr 13, 2005 | Apr 13, 2005 | none ahead |
| Novartisits history only | 60 open or running | phase 4since Sep 12, 2005 | Sep 10, 2005 | none ahead |
| IPCA Laboratoriesits history only | 40 open or running | phase 1since Nov 5, 2012 | Nov 5, 2012 | none ahead |
| Longbio Pharma (Suzhou)its history only | 33 open or running | phase 2since Apr 23, 2026 | Apr 23, 2026 | Jul 16, 2027phase 2 · NCT07816432 |
| Par Healthits history only | 20 open or running | phase 1since Apr 1, 2008 | Apr 1, 2008 | none ahead |
| Ascension Healthits history only | 10 open or running | phase 4since Jan 2, 2018 | Jan 2, 2018 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | no phasesince Sep 1, 2013 | Sep 1, 2013 | none ahead |
| Intarcia Therapeuticsits history only | 10 open or running | phase 1since Dec 21, 2015 | Dec 21, 2015 | none ahead |
| Pharmtechnologyits history only | 10 open or running | phase 1since Sep 20, 2021 | Sep 20, 2021 | none ahead |
Also a collaborator on its studies: PharmaKinetics Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 22 studies since Apr 13, 2005.
- Jun 27, 2023Longbio Pharma’s first study: phase 2 study in Rhinitis, Allergic, SeasonalNew to Longbio PharmaLongbio Pharma · NCT06046391 · 180 enrolled · China
- Jan 18, 2024Phase 2 study in Chronic UrticariaLongbio Pharma · NCT06228560 · 202 enrolled · China
- Feb 3, 20243 phase 1 studiesLongbio Pharma · NCT06294301, NCT06294288, NCT06294275
- Sep 14, 2024Phase 1 study in Chronic UrticariaLongbio Pharma · NCT06604949 · 12 enrolled · China
- Aug 15, 2025Phase 2 study in Allergic DiseasesLongbio Pharma · NCT07148557 · 6 enrolled · China
- Sep 30, 2025Phase 2 study in Hemoglobinuria, ParoxysmalLongbio Pharma · NCT07212426 · 30 enrolled · China
- Nov 24, 2025Phase 2 study in Hemoglobinuria, ParoxysmalLongbio Pharma · NCT07266155 · 30 planned · China
- Dec 5, 2025Phase 3 study in Rhinitis, Allergic, SeasonalPhase 3 reachedLongbio Pharma · NCT07291284 · 546 enrolled · China
- Dec 11, 20252 phase 2 studiesLongbio Pharma · NCT07342803, NCT07313917
- Jan 15, 2026Phase 2 study in Complement-mediated Renal DiseasesLongbio Pharma · NCT07363265 · 46 planned · China
- Apr 23, 2026Longbio Pharma (Suzhou)’s first study: phase 2 study in PeriodontitisNew to Longbio Pharma (Suzhou)Longbio Pharma (Suzhou) · NCT07603713 · 100 planned · China
- Aug 14, 2026Phase 2 study in Peanut HypersensitivityLongbio Pharma (Suzhou) · NCT07785063 · 80 planned · United States, Australia, Canada and more
- Sep 7, 2026Phase 2 study in Food HypersensitivityLongbio Pharma (Suzhou) · NCT07816432 · 12 planned · China
- Nov 9, 2026Phase 3 study in Chronic UrticariaLongbio Pharma · NCT07946913 · 514 planned · China
Ahead
- Nov 2026Primary completion: phase 1 study in Chronic UrticariaLongbio Pharma · NCT06604949
- Nov 12, 2026Primary completion: phase 2 study in PeriodontitisLongbio Pharma (Suzhou) · NCT07603713
- Feb 28, 2027Primary completion: phase 2 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Longbio Pharma · NCT07313917
- Jul 16, 2027Primary completion: phase 2 study in Food HypersensitivityLongbio Pharma (Suzhou) · NCT07816432
TargetBeta
“An orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity”NCIt, by rule
“Angiotensin-converting enzyme inhibitor”ChEMBL 37, by rule
Studies
All 39 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07946913Chronic Urticaria · China | 3 | Not yet recruiting | Longbio Pharma | Mar 24, 2028 | 514 |
| NCT07816432Food Hypersensitivity · China | 2 | Not yet recruiting | Longbio Pharma (Suzhou) | Jul 16, 2027 | 12 |
| NCT07785063Peanut Hypersensitivity · United States, Australia, Canada and more | 2 | Not yet recruiting | Longbio Pharma (Suzhou) | May 2029 | 80 |
| NCT07603713Periodontitis · China | 2 | Not yet recruiting | Longbio Pharma (Suzhou) | Nov 12, 2026 | 100 |
| NCT07363265Complement-mediated Renal Diseases · China | 2 | Not yet recruiting | Longbio Pharma | Aug 2, 2028 | 46 |
| NCT07313917Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) · China | 2 | Not yet recruiting | Longbio Pharma | Feb 28, 2027 | 150 |
| NCT07342803Allergic Asthma · China | 2 | Recruiting | Longbio Pharma | Dec 28, 2027 | 200 |
| NCT07291284Rhinitis, Allergic, Seasonal · China | 3 | Active, not recruiting | Longbio Pharma | Mar 31, 2026 | 546 |
| NCT07266155Hemoglobinuria, Paroxysmal · China | 2 | Not yet recruiting | Longbio Pharma | Dec 30, 2027 | 30 |
| NCT07212426Hemoglobinuria, Paroxysmal · China | 2 | Active, not recruiting | Longbio Pharma | May 6, 2026 | 30 |
| NCT07148557Allergic Diseases · China | 2 | Active, not recruiting | Longbio Pharma | May 31, 2026 | 6 |
| NCT06604949Chronic Urticaria · China | 1 | Active, not recruiting | Longbio Pharma | Nov 2026 | 12 |
| NCT06294288Chronic Urticaria · China | 1 | Completed | Longbio Pharma | Mar 4, 2024 | 60 |
| NCT06294275Myelodysplastic Syndromes · China | 1 | Completed | Longbio Pharma | Aug 16, 2023 | 68 |
| NCT06294301Hemoglobinuria, Paroxysmal · China | 1 | Completed | Longbio Pharma | Aug 31, 2024 | 68 |
| NCT06228560Chronic Urticaria · China | 2 | Completed | Longbio Pharma | Apr 17, 2025 | 202 |
| NCT06046391Rhinitis, Allergic, Seasonal · China | 2 | Completed | Longbio Pharma | Oct 19, 2023 | 180 |
| NCT05061901Bioequivalence · Russian Federation | 1 | Completed | Pharmtechnology | Nov 6, 2021 | 38 |
| NCT03392740Heart Failure, Systolic · United States | 4 | Withdrawn | Ascension Health | Dec 15, 2018 | 0 |
| NCT02641899Healthy · United States | 1 | Completed | Intarcia Therapeutics | Mar 2016 | 33 |
| NCT01936012Healthy · Indonesia | – | Completed | Dexa Medica Group | Feb 2013 | 34 |
| NCT01831700Fasting · India | 1 | Completed | IPCA Laboratories | Oct 2012 | 48 |
| NCT01827878Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | IPCA Laboratories | Oct 2012 | 48 |
| NCT01735344Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | IPCA Laboratories | Aug 2012 | 40 |
| NCT01735318Fasting · India | 1 | Completed | IPCA Laboratories | Aug 2012 | 40 |
| NCT00883506Hypertension | 1 | Completed | Novartis | Jun 2000 | 24 |
| NCT00883064Hypertension | 1 | Completed | Novartis | Apr 2000 | 32 |
| NCT01380431Lecithin Cholesterol Acyltransferase Deficiency · United States | 1 | Completed | Par Health | Oct 1999 | 18 |
| NCT01375244Fasting · United States | 1 | Completed | Par Health | Oct 1999 | 36 |
| NCT00552708Hypertension · United States | 1 | Completed | GlaxoSmithKline | Dec 2007 | 55 |
| NCT00557128Hypertension · United States | 1 | Completed | GlaxoSmithKline | Dec 2007 | 24 |
| NCT00549510Hypertension · United States | 1 | Completed | GlaxoSmithKline | Dec 2007 | 29 |
| NCT00508365Hypertension · United States | 1 | Completed | GlaxoSmithKline | Jun 3, 2008 | 62 |
| NCT00347360Hypertension · United States | 3 | Completed | GlaxoSmithKline | Apr 2008 | 654 |
| NCT00241124Hypertension · Germany | 4 | Completed | Novartis | Jun 2005 | 1,099 |
| NCT00171600Hypertension · Switzerland | 4 | Terminated | Novartis | Jan 2007 | 54 |
| NCT00171574Hypertension · Switzerland | 4 | Completed | Novartis | Jul 2006 | 124 |
| NCT00171067Hypertension · Germany, Switzerland | 3 | Completed | Novartis | May 2007 | 134 |
| NCT00108082Hypertrophy, Left Ventricular · United States | 3 | Completed | GlaxoSmithKline | Aug 2008 | 287 |
How it is read
Names in the registry
- “Lisinopril”, 10 entries
- “LP-003 Injection”, 5 entries
- “lisinopril”, 5 entries
- “LP-005 Injection”, 4 entries
- “LP-003”, 2 entries
Codes read as this program: LP003, LP005, LP001.
Conditions, from the studies’ own filings
- Hypertension, 12 studies
- Chronic Urticaria, 4 studies
- Hemoglobinuria, Paroxysmal, 3 studies
- Fasting, 3 studies
- Rhinitis, Allergic, Seasonal, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.